Literature DB >> 7371714

Specific tricyclic antidepressant binding sites in rat brain characterised by high-affinity 3H-imipramine binding.

R Raisman, M S Briley, S Z Langer.   

Abstract

The specific binding of 3H-imipramine to various brain regions of the rat is of high affinity (Kd = 4.0 nM), rapid and reversible. It was inhibited by tricyclic antidepressants at nanomolar concentrations and by atypical antidepressants at micromolar concentrations. The binding does not seem to be directly related to known neurotransmitter receptor systems. Specific 3H-imipramine binding sites were unequally distributed between the various brain regions and undetectable in the heart and vas deferens. Rats chronically treated with desipramine for three weeks had significantly less specific 3H-imipramine binding sites in the cortex than did control animals. It is concluded that these 3H-imipramine binding sites may be important in the study of depression and of the mechanism of action of antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7371714     DOI: 10.1016/0014-2999(80)90076-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

1.  Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology.

Authors:  B Saletu; J Grünberger; P Anderer; L Linzmayer; H V Semlitsch; G Magni
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

2.  Reduced Bmax of [3H]-imipramine binding to platelets of depressed patients free of previous medication with 5HT uptake inhibitors.

Authors:  M F Poirier; C Benkelfat; H Loo; D Sechter; E Zarifian; A M Galzin; S Z Langer
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Brain 5-hydroxytryptamine uptake sites labeled with [3H]paroxetine in antidepressant drug-treated depressed suicide victims and controls.

Authors:  K M Lawrence; F De Paermentier; S Lowther; M R Crompton; C L Katona; R W Horton
Journal:  J Psychiatry Neurosci       Date:  1997-05       Impact factor: 6.186

4.  Profile of in vitro binding affinities of neuroleptics at different rat brain receptors: cluster analysis comparison with pharmacological and clinical profiles.

Authors:  R Testa; G Abbiati; R Ceserani; G Restelli; A Vanasia; D Barone; M Gobbi; T Mennini
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

5.  Relationship between transmitter uptake inhibition and effects of alpha-adrenoceptor agonists on serotonin and noradrenaline release in the rat brain cortex.

Authors:  M Göthert; E Schlicker; F Köstermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

6.  Unaltered 5-HT- and desipramine-sensitive [3H]imipramine binding and [3H]5-HT uptake in rat brain after chronic imipramine and norzimeldine treatment.

Authors:  J Marcusson; I T Bäckström; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Acute or chronic changes of noradrenergic transmission do not affect the alpha-adrenoceptor-mediated inhibition of 3H-serotonin release in the cerebral cortex.

Authors:  E Schlicker; M Göthert; R Clausing
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

8.  Proceedings of the British Pharmacological Society. Cardiff, 10th-12th April, 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

9.  3H-Imipramine binding sites in the rat brain. Selective localization on serotoninergic neurones.

Authors:  G Gross; M Göthert; H P Ender; H J Schümann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981       Impact factor: 3.000

10.  Short-term lithium administration to healthy volunteers produces long-lasting pronounced changes in platelet serotonin uptake but not imipramine binding.

Authors:  M F Poirier; A M Galzin; C Pimoule; H Schoemaker; K H Le Quan Bui; P Meyer; C Gay; H Loo; S Z Langer
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.